Therapeutic Drug Monitoring Market

Precision Medicine and Personalization to Fuel Therapeutic Drug Monitoring Market Growth

The Therapeutic Drug Monitoring Market is valued at USD 2.8 Bn in 2026 and is projected to reach USD 5.2 Bn,  growing at a CAGR of 10% by 2033. Evolving healthcare domain has introduced various concepts that ultimately support patient outcome. Precision medicine being one such evolving approach for treatment and prevention of diseases has gained significant traction over the past years. Precision medicine revolves around individual variability in human genes, lifestyles and environment. It involves drug selection specifically tailored to the patient based on history and condition of disease. Precision medicine is being used to treat chronic ailments such as cancer by developing drugs entirely based on patient parameters such as tumor analysis, system biology along with gene expression. This analysis considering the absence and presence of pharmacological perturbation can offer a base for developing combination drugs for cancer treatment. The approach of precision medicine is likely to revolutionize pharmacotherapy using therapeutic drug monitoring (TDM).

Moreover, drug personalization can explore the response of patients to drugs which can be used to enhance drug effect while reducing risk of reactions related to sub therapeutic dosing or toxicity. By adopting therapeutic drug monitoring, the drug dosage can be adjusted based on individual pharmacokinetic profile which can improve patient outcome significantly. That said, use of TDM in precision medicine and personalization is expected to influence therapeutic drug monitoring market growth in the coming years.

Wearable Biosensors to Transform the Therapeutic Drug Monitoring Space

Rampant improvements in technology coupled with proliferation of cloud based systems have transformed several industries and healthcare is no exception. That said, adoption of technically advanced wearable biosensors in the therapeutic drug monitoring space is in the offing. Conventional biosensors adopted in therapeutic drug monitoring have laid the foundation for use of advanced systems, thus paving an opportunistic pathway for wearable biosensors. These biosensors offer fast turnaround time, cost effectiveness, require low power and are conveniently portable.

Manufacturers are also focusing on resolving possible challenges associated with use of wearable biosensors in order to facilitate advancement in the therapeutic drug monitoring space. Aspects such as elimination of constant recalibration, establishment of reliable connection between various analyte blood concentrations, detection of new biomarkers, stability, data storage and processing and transmission are being mulled upon. However, with growing technological breakthroughs, these aspects are likely to get resolved triggering use of wearable biosensors and contributing towards therapeutic drug monitoring market growth.

North America Anticipated to Cement Dominance in the Therapeutic Drug Monitoring Market

Developed nations in North America are expected to witness increased demand for therapeutic drug monitoring on the back of growing occurrences of several autoimmune disorders. In addition, growing rate of cardiac deaths has been witnessed due to higher prevalence of cardiovascular disorders. For instance according to CDC (Centers for Disease Control and Prevention), 1 death in every 36 seconds due to cardiovascular diseases has been observed in the United States, making it one of the leading cause of mortalities in the country. Moreover, as per CDC, around 800,000 individuals suffer from heart attack with an average of one attack every 40 seconds.

In addition, according to AHA (American Heart Association) in 2019, about 41% deaths in United States were caused due to coronary heart disease and are likely to increase going forward. This has resulted in an increased demand for therapeutic drug monitoring in order to assess the dosage regimen that can be used to develop treatment for several cardiac indications. Apart from growing burden of heart diseases, other macro aspects such as availability of advanced healthcare technology, superior healthcare infrastructure and government reimbursements followed by stable growth in GDP per capita are also contributing towards growth of therapeutic drug monitoring market in the region. 

Therapeutic Drug Monitoring Market: Competitive Landscape

In wake of noteworthy transformations apropos to convergence between automation, advances in various diagnostic technologies and system engineering backed by stringent regulations, the market is expected to remain optimistic in the coming years. Evolving TDM (therapeutic drug monitoring) space is poised to present new potential opportunities for companies and major players have commenced development of new advanced systems. For instance, in 2020, Bio-Rad introduced anti-certolizumab pegol, a new range of inhibitory antibodies in order to facilitate development of crucial assays for therapeutic drug monitoring of TNF (Tumor Necrosis Factor) alpha inhibitors.

Few of the major players in the therapeutic drug monitoring market include 

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Beckman Coulter (Danaher Corporation)
• bioMérieux S.A.
• Quidel Corporation
• Agilent Technologies
• PerkinElmer, Inc.
• Bio-Rad Laboratories
• Hoffmann-La Roche AG
• Sysmex Corporation
• Instrumental Laboratories (a Werfen Company)
• Tosoh Corporation
• Eurofins Scientific

Global Therapeutic Drug Monitoring Market is Segmented as Below:

By Product Type

• Consumables
• Equipment
• Immunoassay Analyzers
• Chromatography & MS Detectors
• Clinical Chemistry Analyzers

By Technology

• Immunoassays
• Chemiluminescence Immunoassays
• Chemiluminescence Immunoassays
• Colorimetric Immunoassays
• Fluorescence Immunoassays
• Radioimmunoassays
• Other Immunoassays
• Chromatography-MS
• LC-MS
• GC-MS

By Drug Class

• Antiepileptic Drugs
• Antibiotic Drugs
• Immunosuppressant Drugs
• Antiarrhythmic Drugs
• Bronchodilator Drugs
• Psychoactive Drugs
• Other Drug

By End User

• Hospital Laboratories
• Commercial & Private Laboratories

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa